Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury - Concepedia

Concepedia

Publication | Open Access

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

DOI Full Paper Access

166

Citations

41

References

2018

Year

Annayya R. Aroor, Nitin A. Das, Andrea J. Carpenter, Javad Habibi, Guanghong Jia, Francisco I. Ramirez‐Perez, Luis A. Martinez‐Lemus, Camila Manrique‐Acevedo, Melvin R. Hayden, Cornel Duta,

Cardiovascular Diabetology

Abstract

Empagliflozin ameliorates kidney injury in type 2 diabetic female mice by promoting glycosuria, and possibly by reducing systemic and renal artery stiffness, and reversing RECK suppression.

References

	Year	Citations

Page 1